In the evolving field of veterinary medicine, the need for innovative treatments for parasitic infections in pets is more pressing than ever. Parasites such as ticks, roundworms, hookworms, and pinworms are persistent threats to animal health, demanding solutions that are both effective and easy to administer such as oral palatable chewable tablets.
The development of these treatments is a complex, multifaceted challenge that requires not just scientific expertise but also sophisticated manufacturing capabilities. This is where Contract Research and Development Manufacturing Organisations (CRDMOs) play a crucial role, offering a unique blend of research, development, and manufacturing services that can significantly accelerate the delivery of new therapies to the market.
The role of CRDMOs in the pharmaceutical industry, particularly in animal health, is becoming increasingly important as the demand for specialised treatments grows. These organisations offer a strategic advantage by providing end-to-end services, from initial research and development through to large-scale manufacturing. This model allows veterinary pharmaceutical companies to leverage the specialised expertise of CRDMOs, accessing cutting-edge technology and innovative solutions without the need for significant in-house investment.
In the context of anti-parasitic drug development, the challenges are particularly acute. Developing a drug that can effectively target multiple parasites often involves combining several active pharmaceutical ingredients (APIs) into a single formulation. This process requires not only a deep understanding of the pharmacological interactions between these ingredients but also sophisticated techniques to ensure stability, efficacy, and palatability – especially in veterinary medicine, where patient compliance can be difficult to achieve. Moreover, the regulatory landscape for veterinary drugs is becoming increasingly stringent, with higher standards for safety, efficacy, and environmental impact. CRDMOs are well-equipped to navigate this complexity, offering tailored solutions that meet both regulatory requirements and market demands. By partnering with a CRDMO, veterinary pharmaceutical companies can accelerate their development timelines, reduce costs, and mitigate risks, all while maintaining the highest standards of quality.
One company that exemplifies the potential of CRDMOs in this space is Syngene, a leading CRDMO that recently developed an innovative and complex multi-antiparasitic drug formulation for a prominent animal healthcare company.
Syngene partnered with a leading animal health company to deliver a ‘first-in-class’ complex formulation that could treat a range of parasitic infections in dogs, including ticks, roundworms, hookworms and pinworms. The complexity of this task lay in the need to combine multiple APIs into a single tablet, each with its own chemical properties and stability concerns. In addition, the formulation had to be palatable to ensure that dogs would willingly consume the medication, a critical factor in the treatment’s overall effectiveness.
